Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 39; no. 5; pp. 408 - 413
• Main Authors: Liu, X L, Yang, P Y, Yu, X Y, Chen, J C, Bai, J, Liu, Y M, He, H, Sun, J N, Fan, H Q, Zhang, C, Zhang, Y, Su, K J, Liu, C S, Tan, Y H, Gao, S J, Li, W, Jin, F Y
• Format: Journal Article
• Language: Chinese
• Published: China 14.05.2018
• Subjects: Bortezomib - therapeutic use; Chromosome Aberrations; Humans; Multiple Myeloma - drug therapy; Prognosis; Retrospective Studies; 1q21 amplification; Bortezomib; Prognosis; Hematopoietic stem cell transplantation; Multiple myeloma
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2018.05.013

To investigate the effect of 1q21 amplification (1q) on the therapeutic response and prognosis of bortezomib(Btz) in the treatment of newly diagnosed multiple myeloma (MM) patients. A total of 180 newly diagnosed MM were included for analyses of clinical characteristics, cytogenetics, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS), retrospectively. Gene expression profiling (GEP) was analyzed using publicly available R2 platform. ① In 180 patients, 1q was found in 51.1% cases. Of them, 174 patients had complete follow-up data, including 88 cases with 1q and 86 without 1q (non-1q). ②Incidence of 1q was positively associated with percentage of IGH rearrangement (72.2%, =0.017) and 1p deletion (1p) (27.8%, =0.040). ③ The median PFS was 15.0 and 20.3 months for the 1q group and non-1q group, and the median OS was 29.4 and 44.0 months, respectively. Both PFS and OS of 1q group was significantly shorter than those of the non-1q group ( =0.029 and 0.038, respectively). Multivariate analysis further revealed that 1q was an independent prognostic factor for both PFS ( =1.910, 95% 1.105-3.303, =0.020) and OS ( =2.353, 95% 1.090-5.078, =0.029). In 91 evaluable cases with 1q, very good partial remission (VGPR) rate was higher after treatment with Btz than those without Btz (62.1% 40.0%, =0.032). Of note, the patients with 1q who received auto-HSCT after induction with Btz had significantly longer PFS than those without auto-HSCT (19 months 13 months, =0.048). GEP analysis revealed that 1q21 amplification predominantly up-regulated expression of >50% genes within 1q21 region, and also altered expression of 28% genes in chromosome 1 and 10% genes in whole genome, particularly related to DNA repair and cell cycle. 1q is an independent adverse prognostic factor in patients with newly diagnosed MM. It is often associated with 1p deletion and IGH rearrangement. Patients with 1q respond well to Btz-based regimen, but they fail to gain long-term benefit from this treatment itself. However, auto-HSCT following Btz induction might improve survival of patients with 1q, suggesting a potential strategy to treat this high-risk subset of MM. GEP analysis warrants further attention in understanding the mechanisms underlying the high-risk of 1q.